HOME >> MEDICINE >> NEWS
New class of targeted cancer drugs shows promise in slowing progression of recurrent prostate cancer

A new class of targeted anti-cancer drugs that blocks the human epidermal growth factor (HER) receptor family shows promise in prolonging the lives of patients with recurrent prostate cancer, a new Cedars-Sinai study shows. The drug, a molecular targeted compound called pertuzumab, works by binding to and inhibiting the function of HER2 receptors, interrupting a key pathway that leads to cancer growth.

The study, published in the February 20 issue of the Journal of Clinical Oncology, involved 41 patients with treatment-resistant prostate cancer who had experienced progression of their disease after prior chemotherapy. Patients received the drug every three weeks until disease progression. MRI and CAT scans were used to evaluate the tumors during the period of drug therapy. While no shrinkage of tumors was reported, retrospective analysis showed that survival rate was prolonged to 16.4 months with the drug as compared to a median average of 10.7 months in a historical control group with similar baseline prognostic features.

Advanced prostate cancer is difficult to treat and the drug therapies currently available to these patients have not been very effective, especially in patients whose disease has progressed after chemotherapy treatment, said David B. Agus, M.D., principal investigator of the study and research director of Cedars-Sinais Louis Warschaw Prostate Cancer Center at the Samuel Oschin Comprehensive Cancer Institute. Pertuzumab may offer a new treatment approach for these patients when it is evaluated as a tool to slow not stop or shrink -- tumor growth.

The theory is that by significantly slowing progression of the cancer, patients will experience a good quality of life for a longer period of time, said Agus. Ultimately, we hope drugs like pertuzumab will help us reach the point where cancer can be viewed as a lifetime disease to be managed much like AIDS is looked at now. This would be major shift from the current
'"/>

Contact: Simi Singer
simi.singer@cshs.org
310-423-4768
Cedars-Sinai Medical Center
16-Feb-2007


Page: 1 2 3

Related medicine news :

1. W.M. Keck Foundation announces 2007 class of Distinguished Young Scholars in medical research
2. Early-morning Friday classes may prevent students from getting sloppy on thirsty Thursdays
3. Panel offers guidelines on skin reactions to new class of cancer drugs
4. UK researchers find new class of nontoxic cancer treatments
5. New class of HIV drug attacks previously untargeted enzyme
6. Sleep disturbances affect classroom performance
7. Simple classification can help define and predict limb-threatening diabetic infections
8. World-class Biomedical Research Center to be in West London
9. A new way of classifying addictive drugs
10. Phys ed class more effective when theres more talking
11. W.M. Keck Foundation announces 2006 class of Distinguished Young Scholars in Medical Research

Post Your Comments:
(Date:3/27/2015)... 27, 2015 Operatic contenders and their ... on April 17th. The universally acclaimed baritone Sherrill Milnes ... annual Opera Idol at The Merion in Evanston. The ... has drawn aspiring opera singers from around the country. ... of the finest young talent in the country,” said ...
(Date:3/27/2015)... MN (PRWEB) March 27, 2015 ... Minnesotans for Healthy Kids Coalition Lobby Day to ... Statewide Health Improvement Program (SHIP). Everlast Climbing ... 2015 PE Bill SF343/HF498 which would strengthen physical ... annual student assessments and other measures to strengthen ...
(Date:3/27/2015)... Jersey (PRWEB) March 27, 2015 Airy ... has released the official music video for her debut ... , Combining live-action and abstract styling effects, the ... be viewed on YouTube, Vimeo, and assorted outlets. It ... the development of an expanding full-scale marketing strategy. The ...
(Date:3/27/2015)... April 2015 is the 150th anniversary of the ... America’s bloodiest war and the amazing President that led our ... to the Civil War and Abraham Lincoln. This moving event ... the Jane Pickens Theater in Newport, RI. , Chief ... as the master of ceremonies. Dr. Fred Zilian, educator, writer ...
(Date:3/27/2015)... 27, 2015 The Florida Center for ... Cancer Cure (ABC2), awarded $350,000 to support brain cancer ... The Scripps Research Institute and H. Lee Moffitt Cancer ... with a clear development path and potential to provide ... near future. , The awards fund research in ...
Breaking Medicine News(10 mins):Health News:Opera Idol Competition At The Merion In Evanston 2Health News:Everlast Climbing Advocates to Strengthen Physical Education in Minnesota Schools 2Health News:Airy Jeanine Releases ‘’Mama’s Girl” Official Music Video 2Health News:Relive the Civil War, the Presidency and Shocking Assassination of Abraham Lincoln through Lincoln’s Own Words and the Music of a 46-Piece Orchestra 2Health News:Relive the Civil War, the Presidency and Shocking Assassination of Abraham Lincoln through Lincoln’s Own Words and the Music of a 46-Piece Orchestra 3Health News:Relive the Civil War, the Presidency and Shocking Assassination of Abraham Lincoln through Lincoln’s Own Words and the Music of a 46-Piece Orchestra 4Health News:The Florida Center for Brain Tumor Research and Accelerate Brain Cancer Cure Award $350,000 to Florida-Based Researchers 2Health News:The Florida Center for Brain Tumor Research and Accelerate Brain Cancer Cure Award $350,000 to Florida-Based Researchers 3
(Date:3/27/2015)... --  Hospira, Inc. (NYSE: HSP ), ... leading provider of injectable drugs and infusion technologies, ... biosimilarity of its proposed biosimilar, Epoetin Hospira, with ... approved name of RETACRIT™, compared to the reference ... were presented at the National Kidney Foundation (NKF) ...
(Date:3/27/2015)... , March 27, 2015  Delcath Systems, ... and medical device company focused on oncology with ... metastatic liver cancers, announces the reporting of data ... Melphalan Hydrochloride for Injection with the Delcath Hepatic ... poster presentation at the Society of Surgical Oncology ...
(Date:3/26/2015)... 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or ... on Omega-3 therapies for cardiovascular disease and overall health, ... common shares of the Corporation (the "Common Shares"). The ... of December 5 th , 2014 to March 4 ... is due on or before April 1, 2015. Interest ...
Breaking Medicine Technology:Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 5Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2
Cached News: